Drugs / IGIV-C 10%
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00220779 | Dec 2002 → Feb 2005 | relapsing-remitting multiple sclerosis | Grifols Therapeutics LLC | Completed | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IGIV-C 10% | “We therefore set out to test two different doses of a new formulation of immunoglobulin termed IGIV-C 10% for suppression of both clinical and MRI disease activity as well as safety.” PMID 18645164 ↗ Jul 2008 |
| Modality | Protein / enzyme biologic | “a new formulation of immunoglobulin termed IGIV-C 10%” PMID 18645164 ↗ Jul 2008 |
| Route | Intravenous | “Intravenous immunoglobulin in relapsing-remitting multiple sclerosis” PMID 18645164 ↗ Jul 2008 |